Overall, we provided a strategy using nanomedicines to engineer diverse tumor cells into the producers of T-cell chemokines and αPD-L1 inhibitors, which skillfully addressed the two hurdles of αPD-L1 therapy. The gene discussed is TBXT; the disease is neoplasm.